Interestingly, in numerous mouse models of Myc-driven tumors, tumor deterioration via Myc repression is hindered by simultaneous suppression of the TP53 protein, highlighting the relevance of an intact p53 pathway for treating cancer by targeting Myc18–20. Here, MYC is linked to neoplasm.